Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
Presentation to focus on mechanism of action of anti-tumor activity for lead asset YB-200 RIEHEN, SWITZERLAND, April 26, 2023 ─...
top of page
Press Releases
Apr 11, 2023
Ymmunobio Appoints New Chief Operating Officer
Martin E. Zuzulo to guide drug development operations for preclinical-stage biotech company RIEHEN, SWITZERLAND, April 11, 2023 –...
Mar 8, 2023
Ymmunobio Accepted into Innosuisse Core Coaching
Participation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8,...
Mar 2, 2023
Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board
Mitsuro Kanda, MD, PhD, and Vishal Khairnar, PhD, join growing biotech company developing antibodies as therapies against various cancers...
Feb 28, 2023
FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer
Ymmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...
Feb 16, 2023
Ymmunobio Appoints Dr. Caroline Germa to Board of Directors
Medical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...
Feb 8, 2023
Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer
Growing preclinical-stage biotech company adds to executive team RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical...
Jan 31, 2023
Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies
Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers. Read more here: https://www.prnewswire.com/new...
Jan 10, 2023
Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer
Ymmunobio adds to executive team. Read more here: https://www.biopharmadive.com/press-release/20230109-ymmunobio-appoints-dr-michel-janic...
Oct 18, 2022
Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight Session
RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...
Oct 12, 2022
Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of Cancer
Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for...
Jun 13, 2022
Ymmunobio Signs Collaboration Agreement with YUMAB
RIEHEN, Switzerland — Ymmunobio to optimize its antibody development with YUMAB’s antibody technology Ymmunobio AG, a preclinical stage...
Apr 4, 2022
Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH
Agreement expands the company strategy to employ the immune system in the development of cancer therapies RIEHEN, SWITZERLAND, April 7,...
Jan 19, 2022
Ymmunobio AG announces appointment of Dr. Keith Skubitz
Dr. Skubitz, Professor for Hematology & Oncology, University of Minnesota, joins Ymmunobio as scientific advisor for development of...
bottom of page